Sign In
Buy AMGN
$338.22
+9.96 (+3.03%)
At Close: Jun 03, 2026
1 Top Dividend Stock to Buy and Hold Forever
10:45am, Sunday, 01'st May 2022 The Motley Fool
Investors can rest easy with this trusty healthcare giant and its 3% dividend yield.
1 Top Dividend Stock to Buy and Hold Forever
06:45am, Sunday, 01'st May 2022
Investors can rest easy with this trusty healthcare giant and its 3% dividend yield.
The Near Perfect Portfolio For The Good Times And Bad
01:00pm, Saturday, 30'th Apr 2022 Seeking Alpha
With index investing, there's no escape from a roller coaster ride. For most people, especially retirees, it's very difficult to tolerate large and deep drawdowns.
Biopharma can perform well in recession based on past data, says Wells Fargo's Mohit Bansal
03:22pm, Friday, 29'th Apr 2022
Mohit Bansal, Wells Fargo Securities senior equity analyst, joins 'Power Lunch' to discuss biopharma and the market.
AbbVie (ABBV) Q1 Earnings Top, Competition Rises for Imbruvica
03:20pm, Friday, 29'th Apr 2022 Zacks Investment Research
AbbVie (ABBV) beats estimates for first-quarter 2022 earnings while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares decline.
Markets Surge Despite Drop In US GDP
08:10pm, Thursday, 28'th Apr 2022 Benzinga
U.S. indices traded higher Thursday despite a drop in U.S. GDP. Strength in stocks is possibly due to better-than-expected quarterly earnings from multiple companies as well as a rebound following a s
Piper Sandler Maintains Overweight Rating for Amgen: Here's What You Need To Know
04:04pm, Thursday, 28'th Apr 2022 Benzinga
Piper Sandler has decided to maintain its Overweight rating of Amgen (NASDAQ:AMGN) and raise its price target from $255.00 to $260.00.
Shares of Amgen are trading down 5.5% over the last 24 hours, at
Amgen's (AMGN) Q1 Earnings Top, Stock Down on IRS Tax Dispute
02:44pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Amgen (AMGN) beats Q1 estimates for earnings and sales. The stock declines on the announcement of litigation and tax dispute with the IRS.
Where Amgen Stands With Analysts
01:14pm, Thursday, 28'th Apr 2022 Benzinga
Within the last quarter, Amgen (NASDAQ:AMGN) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
2
7
0
0
Last 30D
0
1
2
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
12:52pm, Thursday, 28'th Apr 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Moderna Seeks FDA Emergency Use Nod For COVID-19 Shot In Kids 2-6
Moderna Inc (NASDAQ: MRNA) submitt
Amgen's (AMGN) Q1 Earnings Top, Stock Down on IRS Tax Dispute
12:02pm, Thursday, 28'th Apr 2022
Amgen (AMGN) beats Q1 estimates for earnings and sales. The stock declines on the announcement of litigation and tax dispute with the IRS.
Why Amgen Shares Are Trading Lower
11:12am, Thursday, 28'th Apr 2022
Amgen, Inc. (NASDAQ: AMGN) shares are trading lower by 6.21% at $233.33 after the company reported first-quarter earnings results. Amgen reported quarterly earnings of $4.25 per share which beat the a
Amgen's Q1 Better Than Expected Sales, Profit Overshadowed By Tax Disclosure
06:43am, Thursday, 28'th Apr 2022
Amgen Inc (NASDAQ: AMGN) has recently received a notice of deficiency from the Internal Revenue Service centered on 2013 to 2015. The agency seeks to increase Amgen's taxable income for the period
Amgen (AMGN) Surpasses Q1 Earnings and Revenue Estimates
09:25pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Amgen (AMGN) delivered earnings and revenue surprises of 0.71% and 2.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Amgen Q1 revenue beats expectations, profit declines
09:03pm, Wednesday, 27'th Apr 2022 MarketWatch
Amgen Inc. on Wednesday logged better-than-expected revenue and a decline in profit in the first quarter.
